Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...
Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...
周四,在Globus Medical (NYSE: GMED )宣布以约2.5亿美元股权价值收购Nevro Corp. (NVRO)后,Stifel分析师维持该公司股票的买入评级和92.00美元的目标价。根据InvestingPro数据,Globus Medical保持着优秀的财务状况,整体评分为"优秀",流动性指标强劲。此次交易导致Globus Medical修改了2025年每股收益 ...
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results